Bristol-Myers Squibb Company (BMY) Q2 2019 Earnings Results

Bristol Myers Squibb Beats on EPS, Stock Up 5.02%

Bristol Myers Squibb's strong EPS performance exceeded expectations, which contributed to a positive stock reaction, with shares rising by 5.02%. The company did not provide any updates on future guidance, leaving investors to focus on the current results and the ongoing development of its product pipeline. This quarter's performance may bolster investor confidence as the company continues to navigate the competitive landscape in the pharmaceutical industry.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$1.18	N/A	+8.87%

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed satisfaction with the EPS results, highlighting their commitment to pipeline advancements. They emphasized the importance of continuing to deliver value to patients.

We are pleased with our EPS performance this quarter.

Our focus remains on advancing our pipeline and delivering value to patients.

Bristol Myers Squibb Beats on EPS, Stock Up 5.02%

Key numbers

Management commentary

Bristol-Myers Squibb Company

More earnings this week

Bristol Myers Squibb Beats on EPS, Stock Up 5.02%

Key numbers

Management commentary